Adapted with permission. © Halozyme, Inc. 2018. All rights reserved. © Janssen Pharmaceuticals, Inc.
DARZALEX® SC studies
Overview of the DARZALEX® SC PAVO, COLUMBA and PLEIADES studies
DARZALEX® SC contains recombinant human hyaluronidase PH20 (rHuPH20; ENHANZE® drug delivery technology), an enzyme that disrupts the extracellular matrix to open the subcutaneous space, allowing access to the lymphatic and capillary vessels. The mechanism permits DARZALEX® SC to be absorbed quickly into the systemic circulation.
* Compared with DARZALEX® IV.
IRR: infusion-related reaction
MOA: mode of action
rHuPH20: recombinant human hyaluronidase PH20